EFCG – BPTF Press release 12/02/2020

Active Pharmaceutical Ingredients (API) manufacturers express their concerns and urge EU and US authorities for action as the Coronavirus outbreak in China further highlights the vulnerability of the pharmaceutical supply chain.

Throughout the last year, the European API producers, represented by EFCG, and U.S. manufacturers represented by BPTF, have been alerting regulatory authorities about worsening medicines shortages, actively engaging with them and relevant stakeholders to propose urgent action to alleviate their consequences to our health system. The complex causes and possible solutions to this problem have been detailed in EFCG’s recent position paper.

EFCG and BPTF consider that the availability of vital medicines is every patient’s fundamental right and believe that the current and future critical shortages impact this right. EFCG and BPTF members play a fundamental role in the pharmaceutical supply chain and want to secure the supply chain through pragmatic mitigating actions. They are actively working with the European Union and U.S. authorities and other relevant industry stakeholders to bring a timely solution to this urgent problem.